Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

por Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.
Publicado 2019

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

por Hastings, K, Yu, H A, Wei, W, Sanchez-Vega, F, DeVeaux, M, Choi, J, Rizvi, H, Lisberg, A, Truini, A, Lydon, C A, Liu, Z, Henick, B S, Wurtz, A, Cai, G, Plodkowski, A J, Long, N M, Halpenny, D F, Killam, J, Oliva, I, Schultz, N, Riely, G J, Arcila, M E, Ladanyi, M, Zelterman, D, Herbst, R S, Goldberg, S B, Awad, M M, Garon, E B, Gettinger, S, Hellmann, M D, Politi, K
Publicado 2019

COVID-19 in patients with lung cancer

por Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.
Publicado 2020